Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $80

Benzinga Newsdesk www.benzinga.com Positive 61.4%

Neg 0% Neu 0% Pos 61.4%

Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $75 to $80.